Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) AI Stock Analysis

2 Followers

Hangzhou Tigermed Consulting Co., Ltd. Class H

(Frankfurt:5HZ1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low LeverageTigermed’s low leverage and sizable equity base provide financial flexibility through changing business conditions. Limited debt obligations should reduce balance-sheet strain, preserve capacity to fund operations, and support investment in clinical research capabilities over the next several quarters.

Negative Factors

TTM Net LossThe shift from healthy annual profitability to a TTM net loss is a material deterioration in earnings quality. Sustained losses can weaken internal funding capacity, reduce returns to shareholders, and make future performance more dependent on restoring profitability across the business.

Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 5.02B
Dividend Yield: 0.36%
Average Volume (3M): 7
Price to Earnings (P/E): -103.5
Beta (1Y): 0.61
Revenue Growth: 15.61%
EPS Growth: -171.58%
Country: Germany
Employees: 11,130
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Hangzhou Tigermed Consulting Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trial...

Hangzhou Tigermed Consulting Co., Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:5HZ1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:2359	75Outperform	HKD 537.51B	16.20	30.77%	1.22%	38.26%	84.56%
HK:6127	72Outperform	HKD 37.08B	29.79	13.10%	0.58%	16.68%	442.43%
HK:2268	71Outperform	HKD 92.97B	50.24	14.00%	―	41.52%	17.10%
HK:6667	54Neutral	HKD 1.52B	46.22	4.04%	2.63%	169.02%	-24.61%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:5HZ1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:5HZ1	Hangzhou Tigermed Consulting Co., Ltd. Class H	4.32	-0.44	-9.17%
HK:2359	WuXi AppTec Co., Ltd. Class H	196.60	93.07	89.90%
HK:6127	JOINN Laboratories (China) Co., Ltd. Class H	23.94	4.66	24.20%
HK:6667	Mega Genomics Limited	6.46	-0.57	-8.07%
HK:9860	ADICON Holdings Limited	4.39	-2.00	-31.22%
HK:2268	WuXi XDC Cayman, Inc.	72.05	2.50	3.59%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Hangzhou Tigermed Consulting Co., Ltd. Class H AI Stock Analysis